Patents Assigned to Concert Pharmaceuticals Inc.
  • MORPHINAN COMPOUNDS
    Publication number: 20240117407
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: April 25, 2023
    Publication date: April 11, 2024
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • MORPHINAN COMPOUNDS
    Publication number: 20240093265
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: September 12, 2022
    Publication date: March 21, 2024
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Morphinan compounds
    Patent number: 11473123
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: October 18, 2022
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Deuterated EPI-743
    Patent number: 11267777
    Abstract: This invention relates to novel ?-tocotrienol quinones of Formula I: (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering Vitamin E.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 8, 2022
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Darren H. Wong
  • Morphinan Compounds
    Publication number: 20210348208
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: December 14, 2020
    Publication date: November 11, 2021
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • 4-hydroxybutyric acid analogs
    Patent number: 11161798
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 2, 2021
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20200385330
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: January 10, 2020
    Publication date: December 10, 2020
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Deuterated baricitinib
    Patent number: 10842792
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification, as well as pharmaceutical compositions comprising the same, and methods of using such compounds and compositions to inhibit at least one of Janus Kinase-1 and -2 and diseases associated with those kinases.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 24, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Deuterated idebenone
    Patent number: 10843993
    Abstract: The present invention in one embodiment provides a method of treating Leber's hereditary optic neuropathy, comprising administering to a subject in need of such treatment a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: November 24, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Morphinan compounds
    Patent number: 10813926
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 27, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Deuterated OTX-015
    Patent number: 10683305
    Abstract: This invention relates to novel thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of binding between an acetylated histone and a bromodomain-containing protein.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Julie F. Liu
  • Deuterated analogs of D-serine and uses thereof
    Patent number: 10668036
    Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 2, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
  • Treatment of hair loss disorders with deuterated JAK inhibitors
    Patent number: 10561659
    Abstract: Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 18, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Amanda T. Wagner, James V. Cassella, Philip B. Graham, Virginia Braman, Vinita Uttamsingh, Jana Von Hehn, Colleen E. Hamilton
  • MORPHINAN COMPOUNDS
    Publication number: 20200022975
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 26, 2019
    Publication date: January 23, 2020
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • 4-hydroxybutyric acid analogs
    Patent number: 10532971
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 14, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Deuterated GFT-505
    Patent number: 10442761
    Abstract: This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 15, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Morphinan compounds
    Patent number: 10406155
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 10, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
    Patent number: 10385042
    Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 20, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Substituted triazolobenzodiazepines
    Patent number: 10357499
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 23, 2019
    Assignee: Concert Pharmaceutical, Inc.
    Inventor: Scott L. Harbeson
  • Deuterated idebenone
    Patent number: 10343968
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 9, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung